Magazine Article | February 1, 2022

Scott Gottlieb: The Future Of The CGT Regulatory Paradigm

Source: Life Science Leader

By Anna Rose Welch, Director, Cell & Gene Collaborative
Subscribe to my blog ARW on CGT here!

When I transitioned from the biosimilar industry into the cell and gene therapy (CGT) space, the irony of such a transition wasn’t lost on me. I was making a leap from one end of the innovation and patient access spectrum to the other.

On the one hand, biosimilars are a celebration of what is possible when we know the analytical and clinical profile of a molecule so well that we can replicate it, manufacture it at a large scale, and sell it at a discount. Such a development expands patient access and frees up healthcare funds to cover innovative treatments — including CGT treatments.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader